Skip to main content Skip to search Skip to main navigation

EC: Fifth Notified Body according to IVDR

The European Commission (EC) designated the German company TÜV Rheinland as a Notified Body under the In Vitro Diagnostics (IVDR) Regulation on 1 December 2020.

The IVDR will replace the currently valid IVD Directive (98/79/EC) as of 26 May 2022. With the new IVDR, manufacturers will have to perform conformity assessments for considerably more products.  

Dr. Wilma Hartung, Managing Director Medical Devices at TÜV Rheinland, sees a significant workload coming up for the Notified Bodies: Many manufacturers of in-vitro diagnostics have to be certified for the first time. 

The European Association Medical devices of Notified Bodies (Team-NB) is also concerned. In a position paper published on 25 November 2020, the Team-NB states that Notified Bodies will only support compliance with the current deadlines if the following conditions are met by the end of 2020: 

  • The tools for conducting conformity assessments (e.g. expert:in panels, relevant MDCG guidance documents for classification, performance evaluation etc.) must be available and ready for use.   
  • At least half of the currently existing Notified Bodies should be designated according to the IVDR. Currently, there are five Notified Bodies, but after 31 December 2020 there will be only four, due to the brexit, unless more are added.  

Furthermore, the difficulty to perform QMS audits on site due to Covid-19 is addressed. Team-NB requires a decision on the deadline by the end of 2020 if the conditions cannot be met. 


Sources: 

TÜV Rheinland LGA Products GmbH: TÜV Rheinland: Notified Body for In-Vitro Diagnostics 

EC: NANDO 

Team-NB: Team-NB consideration paper on IVDR Date of Application 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Read more
EMA: Concept Paper on the Revision of Annex 15

EMA: Concept Paper on the Revision of Annex 15

EMA and PIC/S have published a concept paper outlining a targeted revision of Annex 15 (Qualification and Validation).

Read more
Human Resource Management as a Key to Success

Human Resource Management as a Key to Success

The pharmaceutical industry in Germany and other countries, too, faces considerable challenges in the area of human resource management. These problems have far-reaching implications for the competitiveness and innovative power of the industry.

Read more
What do Typical Manufacturing Processes for Sterile Products look like?

What do Typical Manufacturing Processes for Sterile Products look like?

Here's the answer:
Read more
EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

The EMA has published a new reflection paper outlining its current thinking on the qualification of non-mutagenic impurities (NMIs). The paper addresses recommended approaches for evaluating the safety of new or increased impurity levels, particularly when such impurities exceed the ICH Q3A/Q3B qualification thresholds and are identified after completion of non-clinical toxicology studies.

Read more
EMA: Discussions on the Revised ERA Guideline

EMA: Discussions on the Revised ERA Guideline

During the second industry stakeholder webinar on the revised guideline on environmental risk assessment (ERA) for medicinal products for human use, the European Medicines Agency (EMA) addressed key implementation challenges observed during the first year of application.
Read more
Previous
Next